CTXR News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CT

Volume

138.98K

Loading chart

CT

CTXRCitius Pharmaceuticals Inc. Common

CTXR

Pay with—

Available Balance0.00

CT

Mkt Cap

$12.6M

Volume

138.97K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™Citius Pharmaceuticals reported its first revenue of $3.9 million in Q1 2026 following the December 2025 launch of LYMPHIR by its majority-owned subsidiary Citius Oncology. The drug, approved for treating relapsed or refractory cutaneous T-cell lymphoma, has begun initial sales through a nationwide distributor network. The company raised $20.9 million in equity financing and is advancing late-stage pipeline candidates Mino-Lok and Halo-Lido while exploring international expansion and combination therapy opportunities.Benzinga · Feb 13, 2026

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™Citius Oncology reported its first revenue of $3.9 million following the successful December 2025 U.S. commercial launch of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma. The company established nationwide distribution infrastructure and deployed an AI-enabled commercial platform. Despite positive commercial progress, the company reported a net loss of $5.5 million for Q1 2026 and held $7.3 million in cash as of December 31, 2025.Benzinga · Feb 13, 2026

Stock Market Today: Dow Jones, Nasdaq Futures Slip On Christmas Eve Despite Strong Q3 GDP Report— UiPath, AST SpaceMobile, Ramaco In Focus (UPDATED)U.S. stock futures declined slightly on Christmas Eve despite a strong Q3 GDP report showing 4.3% annualized growth. Major indices ended higher on Tuesday, with communication services, IT, and energy stocks leading gains. Several stocks gained attention: UiPath jumped 7% after joining the S&P Midcap 400, Citius Pharmaceuticals rose 8.65% on better-than-expected earnings, Ramaco Resources gained 8% after announcing a $100M buyback, and Multi Ways Holdings surged 62.86% on strong revenue growth.Benzinga · Dec 24, 2025

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq RulesCitius Oncology closed a registered direct offering and private placement, raising approximately $18 million to support the commercial launch of LYMPHIR and for general corporate purposes.Benzinga · Dec 10, 2025

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq RulesCitius Oncology raised $18 million through a registered direct offering and private placement to support the commercial launch of LYMPHIR, a novel cancer immunotherapy for cutaneous T-cell lymphoma, with H.C. Wainwright & Co. acting as the exclusive placement agent.Benzinga · Dec 9, 2025

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private PlacementCitius Oncology closed a $9.0 million registered direct offering and private placement, issuing 5,142,858 shares of common stock and accompanying warrants at $1.75 per share, with warrants exercisable at $1.84 per share.Benzinga · Sep 10, 2025

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private PlacementCitius Oncology has entered a securities purchase agreement to sell 5,142,858 shares of common stock at $1.75 per share, with concurrent warrants, expected to raise approximately $9.0 million.Benzinga · Sep 9, 2025

Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business UpdateCitius Oncology reported its Q3 2025 financial results, highlighting preparations for the commercial launch of LYMPHIR, a therapy for cutaneous T-cell lymphoma, with $12.5 million raised to support pre-launch initiatives.Benzinga · Aug 12, 2025

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business UpdateCitius Pharmaceuticals reported its Q3 2025 financial results, highlighting $12.5 million in gross financings and preparations for LYMPHIR's U.S. launch in Q4 2025. The company experienced a reduced net loss compared to the previous year and continues to advance its oncology and critical care product pipeline.Benzinga · Aug 12, 2025

Citius Oncology Announces Pricing of $9.0 Million Public OfferingCitius Oncology priced a public offering of 6,818,182 shares and warrants at $1.32 per share, expecting to raise approximately $9.0 million to support LYMPHIR commercialization and general corporate purposes.Benzinga · Jul 16, 2025

to start trading

CT

CTXRCitius Pharmaceuticals Inc. Common

CTXR

Pay with—

Available Balance0.00

Your PositionYou don't own any CTXR yet.

Related Tickers

Earnings